Devonian Health Group (CVE:GSD) Stock Price Down 16.6% – Should You Sell?
by Renee Jackson · The Cerbat GemDevonian Health Group Inc. (CVE:GSD – Get Free Report) shares dropped 16.6% on Monday . The company traded as low as C$10.01 and last traded at C$10.01. Approximately 200 shares traded hands during trading, a decline of 84% from the average daily volume of 1,237 shares. The stock had previously closed at C$12.00.
Devonian Health Group Stock Performance
The company has a current ratio of 1.07, a quick ratio of 7.82 and a debt-to-equity ratio of 16.36. The company has a market capitalization of C$27.84 million, a PE ratio of -2.88 and a beta of 1.25. The firm’s 50-day simple moving average is C$12.32 and its 200-day simple moving average is C$11.77.
Devonian Health Group Company Profile
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, the company acquires drug and health product licenses; and distributes pharmaceutical products.